A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
